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Summary

Background In the prevention of cardiovascular disease, a WHO target is that at least 50% of eligible people use
statins. Robust evidence is needed to monitor progress towards this target in low-income and middle-income
countries (LMICs), where most cardiovascular disease deaths occur. The objectives of this study were to benchmark
statin use in LMICs and to investigate country-level and individual-level characteristics associated with statin use.
Methods We did a cross-sectional analysis of pooled, individual-level data from nationally representative health surveys
done in 41 LMICs between 2013 and 2019. Our sample consisted of non-pregnant adults aged 40–69 years. We
prioritised WHO Stepwise Approach to Surveillance (STEPS) surveys because these are WHO’s recommended method
for population monitoring of non-communicable disease targets. For countries in which no STEPS survey was
available, a systematic search was done to identify other surveys. We included surveys that were done in an LMIC as
classified by the World Bank in the survey year; were done in 2013 or later; were nationally representative; had
individual-level data available; and asked questions on statin use and previous history of cardiovascular disease.
Primary outcomes were the proportion of eligible individuals self-reporting use of statins for the primary and secondary
prevention of cardiovascular disease. Eligibility for statin therapy for primary prevention was defined among individuals
with a history of diagnosed diabetes or a 10-year cardiovascular disease risk of at least 20%. Eligibility for statin therapy
for secondary prevention was defined among individuals with a history of self-reported cardiovascular disease. At the
country level, we estimated statin use by per-capita health spending, per-capita income, burden of cardiovascular
diseases, and commitment to non-communicable disease policy. At the individual level, we used modified Poisson
regression models to assess statin use alongside individual-level characteristics of age, sex, education, and rural versus
urban residence. Countries were weighted in proportion to their population size in pooled analyses.
Findings The final pooled sample included 116 449 non-pregnant individuals. 9229 individuals reported a previous
history of cardiovascular disease (7·9% [95% CI 7·4–8·3] of the population-weighted sample). Among those without
a previous history of cardiovascular disease, 8453 were eligible for a statin for primary prevention of cardiovascular
disease (9·7% [95% CI 9·3–10·1] of the population-weighted sample). For primary prevention of cardiovascular
disease, statin use was 8·0% (95% CI 6·9–9·3) and for secondary prevention statin use was 21·9% (20·0–24·0). The
WHO target that at least 50% of eligible individuals receive statin therapy to prevent cardiovascular disease was
achieved by no region or income group. Statin use was less common in countries with lower health spending. At the
individual level, there was generally higher statin use among women (primary prevention only, risk ratio [RR] 1·83
[95% CI 1·22–2·76), and individuals who were older (primary prevention, 60–69 years, RR 1·86 [1·04–3·33];
secondary prevention, 50–59 years RR 1·71 [1·35–2·18]; and 60–69 years RR 2·09 [1·65–2·65]), more educated
(primary prevention, RR 1·61 [1·09–2·37]; secondary prevention, RR 1·28 [0·97–1·69]), and lived in urban areas
(secondary prevention only, RR 0·82 [0·66–1·00]).
Interpretation In a diverse sample of LMICs, statins are used by about one in ten eligible people for the primary
prevention of cardiovascular diseases and one in five eligible people for secondary prevention. There is an urgent
need to scale up statin use in LMICs to achieve WHO targets. Policies and programmes that facilitate implementation
of statins into primary health systems in these settings should be investigated for the future.
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Research in context
Evidence before this study
We searched PubMed on July 5, 2021, without language or date
restrictions using the search terms “statin*” and (“developing
countries” or “low- and middle-income countries” or “lowincome countries” or “middle-income countries”) in the title
and abstract. We identified two large important studies
assessing the use of statins in multiple low-income and middleincome countries (LMICs). The first was the WHO study on
Prevention of REcurrences of Myocardial Infarction and StrokE
(WHO-PREMISE)—a cross-sectional study done at health
facilities in ten LMICs from 2002 to 2003, in which 20% of
patients with a previous history of cardiovascular disease
reported using statins. The second was the Prospective Urban
Rural Epidemiology (PURE) cohort study done in more than
20 high-income, middle-income, and low-income countries.
In baseline data for secondary prevention collected between
2003 and 2009, the PURE study reported statin use of 3·3% for
individuals in low-income countries, 4·3% in lower-middleincome countries, 17·6% in upper-middle-income countries,
and 66·5% in high-income countries. However, these previous
studies used sampling frames that were not nationally
representative, included data collected before statins were
added to the WHO Essential Medicine List in 2007, and did not
estimate statin use for primary prevention using recommended
WHO eligibility criteria.
Added value of this study
To our knowledge, our study provides the most up-to-date and
geographically expansive evidence to track progress towards
the target in the WHO Global Monitoring Framework for noncommunicable diseases that, by 2025, at least 50% of eligible
people with existing cardiovascular disease or at high risk of

Introduction
Ischaemic heart disease and stroke are responsible for
more than a fifth of all deaths worldwide.1 In low-income
and middle-income countries (LMICs), where 80% of
these deaths occur, improving outcomes for cardio
vascular diseases (including heart disease and stroke) is
necessary to achieve Sustainable Development Goal
(SDG) target 3.4 outlined in 2015: a reduction of a
third in premature mortality from non-communicable
diseases by 2030.2 The use of statins to prevent
cardiovascular diseases is an important strategy for
health systems to reduce the population burden of
cardiovascular diseases and to achieve this SDG target.3
Statins are a type of drug that reduce cholesterol
concentration through inhibition of the HMG-CoA
reductase enzyme. According to evidence from clinical
trials demonstrating effectiveness and safety, statins are
widely recommended for the primary and secondary
prevention of cardiovascular diseases4 and have been
included in WHO clinical practice guidelines for
cardiovascular disease prevention and control since 2007.5

cardiovascular disease receive statins. Our study adds value
through three crucial findings. First, in a diverse sample of
nationally representative health surveys from 41 LMICs,
we found that statins were used by about one in ten eligible
people for the primary prevention of cardiovascular disease and
by about one in five eligible people for secondary prevention.
Second, the WHO target that at least 50% of eligible individuals
receive statin therapy to prevent cardiovascular disease was
achieved by no region or income group and by just a single
country (and only for the secondary prevention outcome) in
this set of LMICs. Third, in assessing country-level and
individual-level factors associated with statin use, we observed
less statin use in less wealthy countries, in the African region,
and among traditionally marginalised groups such as those
with less education or living in rural settings.
Implications of all the available evidence
Although there were variations between and within countries,
our study emphasises the crucial need to scale up statin therapy
in LMICs, even relative to other common medicines used to
prevent and control cardiovascular disease such as antihypertensive and glucose-lowering therapies. Policies and
programmes that facilitate implementation of statins into
primary health systems in these settings should be
investigated. A potential approach to scaling up statin use in
LMICs would build on the successful experiences of countries
implementing hypertension care programmes using the WHO
HEARTS framework, which emphasises simplified clinical
protocols, secure procurement of quality-assured medications
and measurement devices, task-sharing among clinical teams,
community-based delivery of care, and strengthened
information systems.

In individuals at high risk, statins are considered costeffective for primary health systems and among a
package of drugs considered the so-called best buys for
non-communicable disease prevention and control.6 A
key target in the WHO non-communicable disease
Global Monitoring Framework is that by 2025, at least
50% of eligible people with existing cardiovascular
diseases or at high risk of these diseases will receive
effective drug therapies including statins.7 This high
frequency of statin use in patients with cardiovascular
diseases has been achieved in high-income countries.8–12
There is a need for rigorous monitoring of populationbased estimates of statin use in LMICs. However, to our
knowledge, there has been no comprehensive evaluation
of statin use in LMICs using nationally representative
samples. Important previous studies assessing statin use
in LMICs used non-representative samples and included
data collected before 20079,13–15 when statins were added
to the WHO Essential Medicines List and became
more affordable via increased generic production.16 The
present study addresses a crucial evidence gap in the
www.thelancet.com/lancetgh Vol 10 March 2022
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current understanding of global cardiovascular disease
prevention by aiming to estimate statin use in LMICs to
track progress towards the WHO target, and investigate
the country-level and individual-level characteristics
associated with statin use.

Methods

Study design and participants
In our cross-sectional study, we analysed individual-level
data from national health surveys done between 2013 and
2019 in 41 LMICs. Our comprehensive methodology for
pooling surveys has been previously described.17,18 We
first identified all LMICs in which a WHO Stepwise
Approach to Surveillance (STEPS) survey had been done.
We prioritised STEPS surveys because they are WHO’s
recommended method for population monitoring of
non-communicable disease targets. To identify other
surveys in countries in which no STEPS survey was
available, we did a systematic internet search in
April, 2020, for each country using search terms and
other details described in appendix 2 (pp 3–4).
We included surveys that met the following criteria:
(1) were done in an LMIC as classified by the World Bank
in the survey year; (2) were done in 2013 or later; (3) were
nationally representative; (4) had individual-level data
available; and (5) asked questions on statin use and
previous history of cardiovascular disease. We chose 2013
as the first year of survey eligibility because this was the
year that STEPS surveys introduced questions on statin
use and cardiovascular disease history. Additional details
on the search process, data availability, and methodology
of the underlying surveys are available in appendix 2
(pp 3–7).
Our sample consisted of non-pregnant respondents
aged 40–69 years. We chose this age range to align with
the WHO non-communicable diseases Global Monitoring
target for drug therapy to prevent cardiovascular diseases
(aged 40 years and older)7 and to encompass the upper age
of 69 years in most surveys.
This study was judged to be exempt from institutional
review board approval by the University of Michigan
(HUM00199295), because the research involved survey
data that could not be linked to a specific individual.

Outcomes and procedures
Our outcomes were the proportion of eligible individuals
self-reporting use of statins for the primary and secondary
prevention of cardiovascular diseases. We defined these
outcomes to align with the monitoring indicator
recommended in the WHO non-communicable diseases
Global Monitoring Framework and WHO HEARTS
Technical Package for cardiovascular diseases manage
ment in primary health care: “Proportion of eligible
persons receiving drug therapy…to prevent heart attacks
and strokes”.7 We defined statin use among respondents
on the basis of the answer to the following question in
STEPS surveys: “Are you currently taking statins
www.thelancet.com/lancetgh Vol 10 March 2022

regularly to prevent or treat heart disease?” We defined
cardiovascular disease history on the basis of the answer
to the following question in STEPS surveys: “Have
you ever had a heart attack or chest pain from heart
disease (angina) or a stroke (cerebrovascular accident or
incident)?”
Eligibility for statin therapy for primary prevention
was defined among individuals without a history of
self-reported cardiovascular disease and with either:
(1) a history of diagnosed diabetes or (2) a 10-year
cardiovascular disease risk of more than 20% using the
2019 WHO laboratory-based risk equations.19,20 These
equations use individual-level inputs of age, smoking
status, systolic blood pressure, history of diabetes, and
total cholesterol. The measurement of biological
variables across surveys is summarised in appendix 2
(pp 30–33). Eligibility for statin therapy for secondary
prevention was defined among individuals with a history
of self-reported cardiovascular disease.

Medicine, Chicago, IL, USA
(M D Huffman); The George
Institute for Global Health,
University of New South Wales,
Sydney, NSW, Australia
(M D Huffman)

Statistical analysis

See Online for appendix 2
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We calculated the proportion of individuals using statins
for the primary and secondary prevention of cardio
vascular disease in the overall pooled sample, by WHO
region and World Bank income group, and by country.
We compared these results with the WHO noncommunicable diseases Global Monitoring Framework’s
2025 target that at least 50% of eligible individuals in the
population receive statin therapy to prevent heart attacks
and strokes.7
To investigate predictors of statin use across countries,
we then plotted statin use for primary and secondary
prevention of cardiovascular disease against four countrylevel characteristics: (1) per-capita health spending in the
year the survey was done; (2) per-capita gross national
income using World Bank estimates in the year the survey
was done; (3) burden of atherosclerotic cardiovascular
disease, as assessed by the sum of disability-adjusted lifeyears per 100 000 people for ischaemic heart disease and
ischaemic stroke, as estimated by the Global Burden of
Disease study;21 and (4) political commitment to noncommunicable diseases, as assessed by a 2019 version of
the non-communicable diseases policy implementation
score. The non-communicable diseases implementation
score ranges from 0–100%, with higher scores reflecting
greater political commitment to these diseases. Countryspecific external data included in our analysis are
presented in appendix 2 (pp 34–35).
To investigate individual-level predictors of statin use
within each country and across the pooled sample, we
regressed statin use on age, sex, education as a marker
of socioeconomic status, and rural versus urban
residence. In the within-country models, we restricted
the regressions to the secondary prevention outcome due
to the low number of individuals using statins for
primary prevention. We used Zou’s modified Poisson
regression with robust error variance because it facilitates
e371
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ISO code

Income
group*

Year†

Response rate‡

Sample size§
(n)

Proportion of
female
participants

Median age, years
(IQR)

Africa
Algeria

DZA

UMIC

2016–17

93·8

3648

54%

50 (44–58)

Benin

BEN

LIC

2015

98·5

2010

48%

50 (44–56)

Botswana

BWA

UMIC

2014

64·0

1511

70%

51 (45–58)

Burkina Faso

BFA

LIC

2013

97·2

1936

48%

49 (44–55)

Eswatini

SWZ

L-MIC

2014

70·0

1360

69%

52 (45–60)

Ethiopia

ETH

LIC

2015

95·5

3236

54%

50 (42–56)
51 (44–59)

Kenya

KEN

LIC

2015

93·0

1750

59%

Uganda

UGA

LIC

2014

92·2

1337

60%

50 (44–57)

Zambia

ZMB

L-MIC

2017

65·0

1597

62%

50 (44–59)

Americas
Ecuador

ECU

UMIC

2018

69·4

2352

57%

52 (45–60)

Guyana

GUY

L-MIC

2016

77·0

1370

57%

52 (46–60)

Mexico

MEX

UMIC

2018–19

98·0

20 287

55%

51 (45–59)

St Vincent and the
Grenadines

VCT

UMIC

2013

67·8

1965

52%

52 (46–58)

Eastern Mediterranean
Afghanistan

AFG

LIC

2018

NA

1621

42%

50 (45–60)

Iran

IRN

UMIC

2016

98·4

14 378

52%

52 (45–59)

Iraq

IRQ

UMIC

2015

93·5

1839

58%

50 (44–59)

Jordan

JOR

UMIC

2019

63·0

2595

59%

51 (45–59)

Lebanon

LBN

UMIC

2017

65·9

1301

58%

53 (47–59)

Morocco

MAR

L-MIC

2017

89·0

2782

63%

52 (45–59)

Sudan

SDN

L-MIC

2016

88·0

3267

57%

50 (45–58)

Europe
Armenia

ARM

L-MIC

2016

42·0

1399

70%

55 (48–61)

Azerbaijan

AZE

UMIC

2017

97·3

1783

60%

55 (48–60)

Belarus

BLR

UMIC

2016

87·0

3453

60%

54 (47–61)

Georgia

GEO

L-MIC

2016

75·7

2938

71%

56 (49–62)

Kyrgyzstan

KGZ

LIC

2013

100·0

1602

63%

51 (46–57)

Moldova

MDA

L-MIC

2013

83·5

3133

62%

55 (49–61)

Tajikistan

TJK

L-MIC

2016

94·0

1330

57%

50 (45–57)

Turkmenistan

TKM

UMIC

2018

93·8

2005

58%

50 (44–58)
49 (44–56)

South-East Asia
Bangladesh

BGD

L-MIC

2018

83·8

3666

47%

Bhutan

BTN

L-MIC

2014

89·9

1343

57%

50 (45–57)

Myanmar

MMR

LIC

2014

90·0

5506

65%

51 (45–57)

Nepal

NPL

LIC

2019

86·4

2662

58%

51 (45–60)

Sri Lanka

LKA

L-MIC

2014

72·0

3148

59%

53 (46–60)

Timor-Leste

TLS

L-MIC

2014

96·3

1334

53%

51 (44–61)
(Table continues on next page)

interpretation of model output as risk ratios (RRs) and is
a valid approach for analysing binary outcomes.22 We also
report the absolute difference in predicted probabilities
using average marginal effects.
We did multiple sensitivity analyses. First, we assessed
statin use for primary prevention only among
individuals aged 40 years and older with no previous
history of cardiovascular disease and estimated 10-year
cardio
vascular disease risk of at least 20% (ie, not
adhering to the WHO recommendation for statin
e372

therapy among all people aged ≥40 years with diabetes).
Second, because the 2019 WHO risk equations were
published after most surveys were done, we reanalysed
the primary prevention outcome using the 2007 WHO/
International Society of Hypertension cardiovascular
disease risk charts and a 10-year cardiovascular disease
risk threshold of at least 30%.5–7 Third, we re-estimated
the pooled regressions without the rural versus urban
residence covariate, because this information was
missing in about a third of the countries (n=14 surveys).
www.thelancet.com/lancetgh Vol 10 March 2022
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ISO code

Income
group*

Year†

Response rate‡

Sample size§
(n)

Proportion of
female
participants

Median age, years
(IQR)

(Continued from previous page)
Western Pacific
Kiribati

KIR

L-MIC

2015

55·0

943

54%

50 (44–57)

Mongolia

MNG

L-MIC

2019

98·0

3415

56%

52 (45–59)

Nauru

NRU

UMIC

2015–16

74·5

461

55%

50 (44–56)

Solomon Islands

SLB

L-MIC

2015

58·4

1155

50%

50 (44–57)

Tokelau

TK

UMIC

2014

70·0

266

53%

51 (46–57)

Tuvalu

TUV

UMIC

2015

76·0

615

55%

53 (47–59)

Vietnam

VNM

L-MIC

2015

79·8

2150

55%

52 (45–59)

··

··

··

86·7 (70·0–93·9)¶

57% (54–60)¶

51 (50–52)¶

Total

116 449

World regions are defined by WHO. ISO=International Organization for Standardization. UMIC=Upper-middle-income country. LIC=low-income country. L-MIC=lowermiddle-income country. NA=not applicable. *Income groups are defined by the World Bank fiscal year categories in the year the survey was done. †Year reflects the year(s) of
survey data collection. ‡Values are the response rate for biochemical measurements, if available, as reported by the survey. §The sample includes non-pregnant individuals
aged 40–69 years of age (40–64 years of age for Burkina Faso, Kyrgyzstan, Myanmar, and Tokelau). ¶Median value and IQR with an equal weighting for each country.

Table: Survey characteristics

Fourth, we rescaled individual survey weights such that
each country was equally weighted in the pooled
analyses.
In all analyses, we accounted for complex survey design
by adjusting for stratification and clustering at the
primary sampling unit using the Stata “svyset” command
with subpopulation specification. Additionally, we applied
sampling weights, which adjust for the probability of
selection, non-response, and differences between the
sample population and the target population. In the main
pooled analyses, we rescaled survey weights using each
country’s 2019 population of people aged 40–69 years and
used country-level fixed-effects. Whenever survey weights
were missing, the country-average weight was assigned to
observations with missing weight values. For all other
data, a complete case analysis was used. Analyses were
done in Stata version 16.1 and R version 4.0.5. Additional
methodological details are provided in appendix 2
(pp 3–7).

Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report.

Results
The final pooled sample included 116 449 non-pregnant
individuals, 50 383 men (49·6% [95% CI 49·0–50·2] of
the population-weighted sample) and 66 066 women
(50·4% [49·8–51·0] of the population-weighted sample).
In the overall sample, 9229 reported a previous history of
cardiovascular disease (7·9% [95% CI 7·4–8·3] of the
population-weighted sample). Among those without a
previous history of cardiovascular disease, 8453 were
eligible for a statin for primary prevention of cardio
vascular disease (9·7% [95% CI 9·3–10·1] of
www.thelancet.com/lancetgh Vol 10 March 2022

Primary prevention
Secondary prevention

WHO target

Statin use (%)

Region
4·5 (2·7–7·5)

Africa

10·4 (8·4–12·7)
10·7 (8·4–13·5)

Americas

16·5 (12·0–22·3)
5·5 (3·6–8·4)

South-East Asia

21·9 (16·9–27·9)
6·3 (2·3–15·8)

Western Pacific

16·9 (12·4–22·6)
5·4 (3·9–7·3)

European

15·7 (13·5–18·3)
13·7 (12·2–15·2)

Eastern Mediterranean

39·4 (35·7–43·3)
Income group
2·0 (0·9–4·7)

Low income

8·2 (6·1–11·0)
6·3 (4·3–9·2)

Lower middle

21·2 (17·5–25·4)
13·8 (12·5–15·3)

Upper middle

31·6 (28·9–34·4)
8·0 (6·9–9·3)

Overall

21·9 (20·0–24·0)
0

20

40

60

Statin use (%)

Figure 1: Pooled estimates of self-reported use of statins for the primary and secondary prevention of
cardiovascular disease in 41 low-income and middle-income countries
The sample includes non-pregnant individuals aged 40–69 years (age 40–64 years for Burkina Faso, Kyrgyzstan,
Myanmar, and Tokelau). Estimates account for survey design and weighting by each country’s 2019 population of
individuals who were aged 40–69 years. The error bars represent 95% CIs. The vertical dashed line represents the
WHO target that at least 50% of eligible people use statins.

the population-weighted sample); table; appendix 2
pp 36–38).
Among the 41 included surveys, there were at least four
countries in each WHO region. Nine surveys were done
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A

Primary prevention
Low-income country
Lower-middle-income country
60
Upper-middle-income country

Statin use for primary prevention (%)

R2=0·3

WHO target
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in low-income countries, 17 in lower-middle-income
countries, and 15 in upper-middle-income countries. In
the pooled sample, self-reported statin use and previous
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history of cardiovascular disease were missing in 0·4%
of the sample (appendix 2 pp 39–40).
In the pooled sample across countries, statin use for
primary prevention was 8·0% (95% CI 6·9–9·3) and for
secondary prevention was 21·9% (20·0–24·0; figure 1).
By region, statin use for both primary and secondary
prevention was highest in the Eastern Mediterranean
region (primary prevention, 13·7% [95% CI 12·2–15·2];
secondary prevention, 39·4% [35·7–43·3]) and lowest in
Africa (primary prevention, 4·5% [2·7–7·5]; secondary
prevention, 10·4% [8·4–12·7]. By World Bank income
group, there was a positive gradient between statin use
and country-level economic development, including a
seven-fold greater use of statins for primary prevention
(from 2·0% [95% CI 0·9–4·7] to 13·8% [12·5–15·3]) and
four-fold greater use for secondary prevention (from
8·2% [6·1–11·0] to 31·6% [28·9–34·4]) within uppermiddle-income countries than in low-income countries.
No region or income group achieved the WHO target of
50% use of statins among eligible individuals in the
population. At the country level, only Iran achieved the
WHO target for secondary prevention, and no country
achieved the target for primary prevention (appendix 2
pp 41–42).
Of country characteristics examined, per-capita health
spending accounted for most statistical variation in the
observed statin use (R²=0·30 for primary prevention and
R²=0·26 for secondary prevention; figure 2; appendix 2
43–45). Examples of countries that appeared to have
greater than predicted statin use based on health spending
included Iran, Jordan, Lebanon, and Sri Lanka. Per-capita
income (primary prevention, R²=0·21; secondary pre
vention, R²=0·19), non-communicable diseases policy
commit
ment (primary prevention, R²=0·05; secondary
prevention, R²=0·11), and estimated burden of cardio
vascular disease (primary prevention, R²<0·01; secondary
prevention, R²=0·01) accounted for less statistical
variation in observed statin use.
Although there was heterogeneity across countries,
characteristics of older age, higher educational
attainment, and urban residence were associated with
greater use of statins for secondary prevention in the
within-country models (figure 3; appendix 2 pp 46–53).
In the multivariable regressions of statin use in the
pooled sample, older age was associated with higher
statin use for both primary prevention (60–69 years
RR 1·86 [95% CI 1·04–3·33]) and secondary prevention
(50–59 years RR 1·71 [1·35–2·18] and 60–69 years RR 2·09
[1·65–2·65]; figure 4). Women were more likely than were
men to use statins for primary prevention (RR 1·83
[95% CI 1·22–2·76]) but not secondary prevention
(RR 0·95 [0·80–1·13]). Individuals with secondary or
higher education were more likely to use statins than
were those with no schooling (primary prevention,
RR 1·61 [95% CI 1·09–2·37]; secondary prevention,
RR 1·28 [0·97–1·69]). Rural residence was associated
with lower use of statins than was urban residence for
www.thelancet.com/lancetgh Vol 10 March 2022
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Figure 3: Relative and absolute differences in statin use for secondary prevention of cardiovascular disease by country using modified Poisson regressions for sex (A), age (B), education (C),
and residence (D)
All regressions were adjusted for sex and age. Age was included in three categories (40–49 years, 50–59 years, and 60–69 years) for all the regressions except for in (B) age, in which it was dichotomised
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secondary prevention (RR 0·82 [95% CI 0·66–1·00]) but
not primary prevention (RR 0·81 [0·52–1·26]).
The sensitivity analyses assessing statin use for
primary prevention among individuals aged 40 years and
older with 10-year cardiovascular disease risk of more
than 20% (ie, removing the universal indication for
www.thelancet.com/lancetgh Vol 10 March 2022

statins among people with diabetes), using the 2007
WHO/International Society of Hypertension cardio
vascular disease risk charts with 10-year cardiovascular
disease risk threshold of at least 30%, and excluding the
rural versus residence variable, were consistent with the
main analyses. The sensitivity analysis using equal
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Figure 4: Relative and absolute differences in statin use across the pooled sample using modified Poisson
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country weights showed slightly lower estimates for
overall statin use for primary (6·7% [95% CI 5·8–7·7])
and secondary (15·9% [14·7–17·2]) prevention of
cardiovascular disease. The remainder of the results
from this sensitivity analysis mirrored the patterns of
individual-level associations with statin use that were
observed in the main analyses. Full results from these
sensitivity analyses are provided in appendix 2 (pp 54–60).

Discussion
In a geographically and economically diverse sample of
nationally representative surveys from 41 low-income
and middle-income countries, we found that statins were
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used by approximately one in ten eligible people for the
primary prevention of cardiovascular disease and one in
five eligible people for the secondary prevention of
cardiovascular disease. The WHO target that at least 50%
of eligible individuals receive statin therapy to prevent
cardiovascular disease was achieved by no region or
income group and by just a single country (and only
for secondary prevention) in this set of LMICs. At the
country level, statin use was lower in countries with
lower health spending. At the individual level, there
was generally lower statin use among men (primary
prevention only) and individuals who were younger, less
educated, or lived in rural areas. These estimates provide
the first nationally representative and most geographically
expansive evidence about the patterns of statin use in
many LMICs. Our findings can serve to evaluate progress
towards global non-communicable disease targets and to
guide health systems’ responses to the large and rising
cardiovascular disease burden in LMICs.
Statins are widely recommended in clinical practice
guidelines and were added to the WHO Essential
Medicine List in 2007.5,16 Nevertheless, we find that statin
use for cardiovascular disease has remained very low.9 By
contrast, in surveys done in the USA and other highincome countries, statin use is 60–70% for secondary
cardiovascular disease prevention8,9 and approximately
50% for primary cardiovascular disease prevention in
people with diabetes or a 10-year cardiovascular disease
risk of at least 20%.10–12 Statin use is much higher in the
upper-middle-income countries than in the lowermiddle-income or low-income countries included in our
study. Previous work using pooled surveys from LMICs
has demonstrated that about three quarters of people
with diagnosed hypertension take antihypertensive
medications,17 and 85% of people with diagnosed
diabetes take glucose-lowering medications.23 Given the
disproportionate burden of cardiovascular disease in
LMICs and the strong clinical evidence supporting statin
therapy, our findings emphasise the urgent need to scale
up statin use relative to other medicines to prevent and
control non-communicable diseases.
Important previous studies assessing the use of statins
in multiple LMICs include the WHO study on Prevention
of REcurrences of Myocardial Infarction and StrokE
(WHO-PREMISE)15 and the Prospective Urban Rural
Epidemiology (PURE) study.9,13,14 WHO-PREMISE was a
cross-sectional study at health facilities in ten LMICs
from 2002 to 2003 in which 20% of patients with a
previous history of cardiovascular disease reported using
statins.15 PURE is a prospective cohort study done in
more than 20 high-income, middle-income, and lowincome countries. In baseline data collected between
2003 and 2009, statin use for secondary prevention was
reported by 3·3% of individuals in low-income countries,
4·3% in lower-middle-income countries, 17·6% in uppermiddle-income countries, and 66·5% in high-income
countries.9 Most of the variation in statin use was
www.thelancet.com/lancetgh Vol 10 March 2022
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explained by between-country differences,9 but there
were differences observed by individual-level character
istics such as socioeconomic position.13
Our study adds to the evidence previously provided by
WHO-PREMISE and PURE to substantially advance the
understanding of statin use globally for many LMICs.
First, previous studies used sampling frames that were
not strictly representative compared with nationally
representative data used in the current study. Such
nationally representative estimates are preferred by
WHO to monitor progress in meeting non-communicable
disease targets.7 Second, we compiled the most recently
available survey data (2013 or later) on statin use in
LMICs. By contrast to previous studies, all surveys
included in our study were done after simvastatin was
added to the WHO Essential Medicine List in 2007 and
after statin patents expired in the USA (2006–12), which
was associated with large decreases in international
prices for statins.16,24 Third, we include a much larger
sample of countries than did WHO-PREMISE or PURE.
Fourth, a novel aspect of our study is that we estimate
statin use not only for secondary prevention of cardio
vascular disease, but also for primary prevention by
applying eligibility criteria from recently updated WHO
clinical guidelines and risk equations.19,20 Finally, our
study uses the most up-to-date data available to track
progress towards the stated target for statin therapy
in the WHO Global Monitoring Framework for noncommunicable diseases.7
An important finding in our study was the substantial
variation in statin use between countries. We found that
country-level characteristics explained only a modest
amount of the observed between-country differences in
statin use. For example, the variation in per-capita health
spending explained approximately a quarter of the
variance in statin use for secondary prevention (R²=0·26)
in our study, which is substantially lower than in the
PURE study (R²=0·77), although PURE also included
data from high-income countries.9 Our comparisons also
allowed us to identify countries where statins were more
commonly used than what would be predicted on the
basis of health spending or other country characteristics
alone. Examples included several countries in the Eastern
Mediterranean WHO region, including Iraq, Iran,
Jordan, and Lebanon. The results from Iran are notable
because it was the only country in our sample that has
already achieved the 2025 WHO non-communicable
disease target of 50% statin use for secondary prevention
of cardiovascular disease, although this was not the case
for primary prevention. Potential explanations for these
observations in Iran include the country’s political
commitment to non-communicable diseases, establish
ment of a multisectoral national non-communicable
diseases committee, and prioritisation of interventions
classified by WHO as so-called best buys.25 Our findings
can inform subsequent health system research
investigating the underlying reasons why some health
www.thelancet.com/lancetgh Vol 10 March 2022

systems—including those in countries with low percapita health spending—are more likely to offer statin
therapy to eligible individuals.
At the individual level, although there was heterogeneity
among surveys, we found greater statin use among
individuals who were older, had greater educational
attainment, and lived in urban rather than rural areas,
which was generally consistent with previous studies.9,15
In previous research on hypertension and diabetes care
in LMICs, older age and higher education have emerged
as strong predictors of diagnosis, treatment, and control
of these conditions.17,18 The greater use of statins for
primary prevention of cardiovascular disease among
women has also been reported in the PURE study.26
However, unlike in the PURE study, women with a
previous history of cardiovascular disease had similar
rates of statin use to those of men in our study.
Several reasons might explain the lower use of statins
relative to other cardiovascular disease medicines in
LMICs. Cholesterol measurements are typically more
costly than measurements of other risk factors such as
blood pressure or blood glucose. Previous clinical
guidelines focused on cholesterol target concentrations
for statin initiation and monitoring, so these higher
measurement costs might have led clinicians and policy
makers to focus less on statins. Additionally, the burden of
cardiovascular disease attributable to elevated cholesterol
has been lower than that attributable to elevated blood
pressure in cohort studies.27 As a result, national policies
might have prioritised blood pressure medications over
statins even though the relative risk reduction for statin
therapy is similar to that of anti-hypertensive therapy.28 An
example demonstrating this dynamic is that statins were
added to the WHO Essential Medicine List in 2007,16 yet
statins are included in national essential medicines lists in
only two thirds of LMICs—a lower proportion than other
essential cardiovascular disease medicines.3,29 Finally,
statins are less affordable in LMICs than are other
medicines used to prevent and control cardiovascular
disease, as documented by PURE’s finding that statins
cost 17% of discretionary household income in urban
areas and 49% in rural areas of low-income countries.30
International prices for statins are similar to those of these
other medicines,31 suggesting that procurement prices
alone are probably insufficient to explain the low statin
use observed in our study.
The WHO HEARTS Technical Package provides a
template for implementing multilevel strategies to scale
up statin use in LMICs.32 Along with structural enabling
factors such as health system capacity for point-of-care
lipid testing and political buy-in to harness necessary
investments, relevant HEARTS package components
include simplified clinical protocols, secure procurement
of quality-assured medications and measurement
devices, task-sharing among clinical teams, communitybased delivery of care, and strengthened information
systems.32 In settings with limited laboratory capacity,
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greater use of non-laboratory risk scores could support a
risk-based approach to cardiovascular disease prevention,
as recommended in HEARTS. Finally, fixed-dose comb
ination medications (ie, so-called polypills), which are
effective in reducing cardiovascular disease,33 also have
the potential to increase appropriate use of both statins
and blood pressure medications.
Our study has several limitations. First, we rely on selfreported measures of a previous history of cardiovascular
disease and statin use. We justify using these self-reported
measures as they are the recommended methodology
in the WHO non-communicable disease Monitoring
Framework.7 To our knowledge, there is no research
validating self-reported medical history or medication use
in STEPS surveys. Previous studies support the reliability
of self-reports of cardiovascular disease history, including
accuracy of 89% in the PURE study.9 Self-reports for
cardiovascular disease medications have also been found
to have high levels of accuracy in previous studies.34,35
Second, we were unable to capture important details of
medication use such as the specific statin agent or dose,
whether the statin was generic or branded, and whether
the respondent had taken statins in the past but stopped
them due to side-effects. Although these details would
not have affected our estimates of statin eligibility as
defined by WHO, it would have allowed us to comment
on the appropriateness of statin intensity, cost, and other
factors. Third, our findings are mainly generalisable to
the countries in which surveys were done, and we were
unable to include surveys from some large LMICs, such
as China and India. Results at the country level should
be interpreted with caution. However, our study is unique
in its use of nationally representative, individual-level
data from surveys done in a diverse set of countries that
collectively represent a total population of more than
1 billion people. In future research, we hope to assess
statin use using harmonised data from countries of all
income levels. Fourth, we did not assess statin use by
target lipid concentrations—an approach recommended
in previous guidelines and applied in our group’s previous
work36—because low-density lipoprotein cholesterol data
were unavailable in approximately two-thirds of surveys.
Finally, our analyses of statin use for primary prevention
rely on cardiovascular risk scores developed by WHO that
might not be accurately calibrated to all countries in
our analysis.
In conclusion, our results emphasise the urgent
need to scale up statin use in LMICs, where most of the
global cardiovascular risk burden occurs. Policies and
programmes that facilitate the successful implementation
of statins into primary health systems in these settings
must be investigated in future research and advocacy.
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